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Average pain relief: OXN −4; OP −2,5; (p<0.01). – Both clinically and signiﬁcantly favorable bowel function change, in patients
treated with OXN −19.5 vs OP +6.5 (p<0.01).
Conclusions. Cancer patients treated with opioids signiﬁcantly improve their QOL. Maintained opioid treatment with OXN shows
signiﬁcant improvements in QOL, pain relief and bowel function.
http://dx.doi.org/10.1016/j.rpor.2013.03.387
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Introduction. Laryngeal plasmacytomas are very uncommon and few cases are described. We present a patient with multiple
myeloma who has been diagnosed with thyroid cartilage plasmocytoma.
Case. 74 year-old man diagnosed in 2004 of a solitary vertebral plasmacytoma treated with external beam radiotherapy at D5 level.
In 2009, multiple plasmocytomas evidenced along vertebral column. New irradiation was desestimated because of the previous
treatment. Was treated by arthrodesis (D2–D7). A new progression in 2010 was treated with corticoids. He was diagnosed of an
IgAl oligosecreator myeloma and started melfalan-bortezomib-prednisone therapy, achieving a complete response after 6 cycles.
In 2012 was detected swelling in left zygomatic area. Tomographic scanner showed a lytic lesion in left orbit with extension to
the zygomatic bone. Histologic study conﬁrmed plasmacytoma. External beam radiotherapy 30Gy was done at this level with
a partial response. During CT simulation, we detected a new lytic lesion in the thyroid cartilage with associated soft tissue
involvement. For now, is pending perform radiotherapy (20Gy) and subsequent systemic treatment.
Discussion. Plasma cell neoplasms are characterized by neoplastic proliferation of a single clone of plasma cells. They can
present as solitary plasmacytoma (SP), extramedullary plasmacytoma (EP) and multiple myeloma. Solitary plasmacytomas most
frequently occur in bone, involving large bones and axial skeleton. Head and neck location is not frequent. Extramedullary
plasmacytomas (EP) affect submucosal areas and are most often located in head and neck region (80%), mainly in the upper
aerodigestive tract, althought uncommon laryngeal location (<7%). EP can arise in patients with multiple myeloma at any time
during the course of the disease. Plasmacytomas are radiosensitive tumors. Radiotherapy in these tumors may provide a good
local control and symptomatic control of the disease.
Conclusion. Plasmacytomas located in laryngeal area are very uncommon. It is needed and histological conﬁrmation and radio-
therapy is a good treatment option.
http://dx.doi.org/10.1016/j.rpor.2013.03.388
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Background. Medulloblastoma is one of the most common childhood brain malignancies.
Aim. The purpose of this study is to evaluate the tolerability and prognostic factors for toxicity of craniospinal irradiation (CSI)
with helical tomotherapy (HT) in the treatment of medulloblastoma.
Materials and methods. The study was conducted for 19 pediatric patients with primary medulloblastoma (standard risk, N=10;
high risk, N=9) treated with craniospinal HT from May 2007 through December 2010. HT regimens to the neuroaxis included:
23.4Gy at 1.8Gy/fraction (N=10), 36Gy at 1.8Gy/fraction (N=7), and 39Gy bid at 1.3Gy/fraction (N=2). The tumor bed received
54–60Gy at 1.5–1.8Gy/fraction. Spearman’s rank correlation coefﬁcient was used to correlate patient, tumor, and dosimetric
factors with the grade of acute toxicity or the overall survival time.
Results. The median age at diagnosis was 5 years (range, 2–14) and the median follow-up for alive patients (N=14) 40 months
(range, 10–62). Two and three-year overall survival was 75% and 68%, respectively. Only 2 patients had a local failure in the
surgical bed. The most common acute toxicity was hematological (79%), being grade 2 and grade 3 in 4 (21%) and 11 (58%) cases,
respectively. Speciﬁcally, grade 3 acute anemia, neutropenia, and thrombopenia was observed in 5% (N=1), 53% (N=10), and 10%
(N=2), respectively. Therewere no cases of grade 4 acute toxicity. Non grade ≥2 late toxicitieswere observed. Longer time between
diagnosis and radiation therapy associated with shorter overall survival (P=0.03). Older children associated with higher grades of
acute body toxicity (P=0.004), whereas longer radiation treatments associated with higher grades of acute hematological toxicity
(P=0.034).
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Conclusion. Clinical outcomes of CSI schedule with HT are favorable, with lower resultant doses to the normal tissue. Acute and
late toxicities are tolerable without severe late side effects.
http://dx.doi.org/10.1016/j.rpor.2013.03.389
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Introduction. On the 16th of January 2012, the Spanish Association Against Cancer (AECC) implemented the volunteer program
“Carrito Don Amable” in the Radiation Oncology Service of Meixoeiro Hospital of the University Hospital Center of Vigo (CHUVI)
with the aim of taking care the needs that are not met under the healthcare scope, both for the oncologic patients and for his
relatives. One year after its implementation, it will be carried out a quality assessment of the program, taking into account the
importance and the assessment of the attributes made by patients and relatives that are program beneﬁciaries.
Objective. Analyzing the quality of the program “Carrito DonAmable” of the AECC, implemented in the RadiationOncology Service
of the CHUVI through the IPA Technique (Importance-Performance Analysis) in a representative sample of program beneﬁciaries.
Methods. The IPA is a quality assessment technique based on the analysis of expectation together with the assessment of the
attributes of the applicable service. In this study, it is implemented a questionnaire fulﬁlled by a statistically signiﬁcant sample
of the patients and relatives beneﬁciaries of the program.
Results and conclusions. Quadrant graphics will represent those attributes of the program that could be improved, those that will
be improved as a priority, those attributes that could imply a waste of resources or those of low priority. We will measure the
general success of the program assessed by its beneﬁciaries, the patients and relatives.
http://dx.doi.org/10.1016/j.rpor.2013.03.390
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Melanoma is a cancer that develops in melanocytes, the pigment cells present in the skin. It can be more serious than the other
forms of skin cancer because it may spread to other parts of the body (metastasize) and cause serious illness and death. About
40,000 new cases of melanoma are diagnosed in the United States every year. Health-related quality of life and survival are two
important outcome measures in melanoma research and practice. The aim of this presentation is to examine the relationship
between quality of life data and survival time in patientswithmelanomausing a general, validated dermatology QOL instrument:
the Dermatology Life Quality Index (DLQI). A total of 25 patients with melanoma were studied on the relationship between
quality of life and survival and we were found to be relevant and that were further examined. With few exceptions, the ﬁndings
showed that quality of life data or some aspects of quality of life measures were signiﬁcant independent predictors of survival
duration. Global quality of life, functioning domains and symptom scores – such as appetite loss, fatigue and pain – were the
most important indicators, individually or in combination, for predicting survival times in cancer patients after adjusting for one
or more demographic and known clinical prognostic factors. This review provides evidence for a positive relationship between
quality of life data or some quality of life measures and the survival duration of cancer patients. Pre-treatment (baseline) quality
of life data appeared to provide the most reliable information for helping clinicians to establish prognostic criteria for treating
their patients. It is recommended that future studies should use valid instruments, apply sound methodological approaches and
adequate multivariate statistical analyses adjusted for socio-demographic characteristics and known clinical prognostic factors
with a satisfactory validation strategy.
http://dx.doi.org/10.1016/j.rpor.2013.03.391
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Background. Delayed complications should be taken into account for treatment and routine follow-up of patients with soft tissue
sarcomas (STS), in order to prevent alterations in bone growth, osteitis, or secondary stress fractures.
